申请人:Boehringer Ingelheim Limited
公开号:US04722926A1
公开(公告)日:1988-02-02
Compounds of the formula ##STR1## wherein R is hydrogen or ##STR2## A is alkyl of 1 to 8 carbon atoms; cycloalkyl of 3 to 7 carbon atoms; phenyl; or phenyl mono-, di- or tri-substituted independently with alkyl of 1 to 4 carbon atoms, halogen, trihalomethyl, alkoxy of 1 to 3 carbon atoms, carboxylic acyl of 1 to 3 carbon atoms, carboxyl, (alkoxy of 1 to 3 carbon atoms)carbonyl, nitro, cyano or di(alkyl of 1 to 3 carbon atoms)amino; R.sub.1, R.sub.2 and R.sub.3, are independently hydrogen, halogen, alkyl of 1 to 4 carbon atoms, trihalomethyl, nitro, cyano, di(alkyl of 1 to 4 carbon atoms)amino, (alkoxy of 1 to 4 carbon atoms)carbonyl, alkoxy of 1 to 4 carbon atoms or hydroxyl; R.sub.4 and R.sub.5 are independently hydrogen, alkyl of 1 to 4 carbon atoms, or phenyl; R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are independently hydrogen or methyl; Y is --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --; j is 0 to 1; k and m are independently 0, 1, 2, or 3, their sum being no more than 6 and must be 0 when j is 1; n is 2, 3, or 4, with the proviso that n must be 3 or 4 when R.sub.1 is hydrogen or 2-methyl, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R are each and j, k, and m are each 0, and Y is --CH.sub.2 --; and non-toxic, pharmaceutically acceptable acid addition salts thereof are useful for the treatment of immunological, inflammatory and allergic disorders.
公式 ##STR1## 中的化合物,其中 R 是氢或 ##STR2##,A 是1至8个碳原子的烷基;3至7个碳原子的环烷基;苯基;或苯基独立地单取代、双取代或三取代烷基,卤素,三卤甲基,1至3个碳原子的烷氧基,1至3个碳原子的
羧酸酰基,羧基,(1至3个碳原子的烷氧基)羰基,硝基,
氰基或二(1至3个碳原子的烷基)
氨基;R.sub.1、R.sub.2和R.sub.3独立地是氢、卤素、1至4个碳原子的烷基,三卤甲基,硝基,
氰基,二(1至4个碳原子的烷基)
氨基,(1至4个碳原子的烷氧基)羰基,1至4个碳原子的烷氧基或羟基;R.sub.4和R.sub.5独立地是氢、1至4个碳原子的烷基或苯基;R.sub.6、R.sub.7、R.sub.8和R.sub.9独立地是氢或甲基;Y是--CH.sub.2--或--CH.sub.2--CH.sub.2--;j为0至1;k和m独立地为0、1、2或3,它们的和不超过6,当j为1时必须为0;n为2、3或4,但当R.sub.1为氢或2-甲基,R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8、R.sub.9和R均为0,j、k和m均为0,Y为--CH.sub.2--时,n必须为3或4;以及其非毒性、药学上可接受的酸盐对免疫、炎症和过敏性疾病的治疗有用。